Bioregenx (BRGX) Beginning Cash Balance (2022 - 2023)
Bioregenx's quarterly Beginning Cash Balance came in at $190891.0 in Q4 2023, up 27170.14% year-on-year from N/an in Q4 2022, and up 210.41% quarter-over-quarter from -$172890.0 in Q2 2023.
Bioregenx has reported Beginning Cash Balance for 2 years, with the latest figure at $190891.0 in Q4 2023.
- For the quarter ending Q4 2023, Beginning Cash Balance rose 27170.14% year-over-year to $190891.0; the trailing twelve-month figure through Mar 2024 stood at $18001.0 (down 37.86% YoY), and the FY2023 full-year result was $191001.0, up 27185.86% from the prior year.
- Beginning Cash Balance for Q4 2023 stood at $190891.0, up from -$172890.0 in the prior quarter.
- The five-year high for Beginning Cash Balance was $190891.0 in Q4 2023, with the low at -$172890.0 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn |
| 10 | Bioregenx | - | - | 348,288.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 190,891.00 |
| Dec 31, 2023 | 190,891.00 |
| Jun 30, 2023 | -172,890.00 |
| Jun 30, 2023 | -172,890.00 |
| Mar 31, 2023 | 28,270.00 |
| Mar 31, 2023 | 28,270.00 |
| Dec 31, 2022 | 700.00 |
| Dec 31, 2022 | 700.00 |